NCT06465914 2024-12-12A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesShanghai Bovax Biotechnology Co., Ltd.Phase 3 Active not recruiting9,000 enrolled